FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Trump Signs Order to Cut Routine Childhood Vaccines 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Add as a preferred source on Google
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
